Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Summary

The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications